ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer
Sonpavde, Guru, Necchi, Andrea, Gupta, Shilpa, Steinberg, Gary D, Gschwend, Juergen E, Van Der Heijden, Michiel Simon, Garzon, Nathalie, Ibrahim, Mohammed, Raybold, Bradley, Liaw, Danny, Rutstein, Mark, Galsky, Matt D
Published in Future oncology (London, England) (01.01.2020)
Published in Future oncology (London, England) (01.01.2020)
Get full text
Journal Article
Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress)
Van Der Heijden, Michiel Simon, Gupta, Shilpa, Galsky, Matt D., Derleth, Christina Louise, Lee, Sue, Kataria, Ritesh S., Powles, Thomas
Published in Journal of clinical oncology (20.02.2022)
Published in Journal of clinical oncology (20.02.2022)
Get full text
Journal Article
Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC)
Gupta, Shilpa, Fujii, Yasuhisa, Van Der Heijden, Michiel Simon, Weickhardt, Andrew James, James, Nicholas D., Shariat, Shahrokh F., Michalski, Jeff M., Imai, Kentaro, Fang, Xiao, Kapadia, Ekta, Shore, Neal D.
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible
Grivas, Petros, Van Der Heijden, Michiel Simon, Necchi, Andrea, Siefker-Radtke, Arlene O., Cutuli, Hernan, Qureshi, Anila H., Kreiser, Stephanie, Hodari, Moana, Ravimohan, Shruthi, Zakharia, Yousef
Published in Journal of clinical oncology (20.02.2022)
Published in Journal of clinical oncology (20.02.2022)
Get full text
Journal Article
SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy
Van Der Heijden, Michiel Simon, Cutie, Christopher, Hampras, Shalaka, Indoria, Charu, Stewart, Rachel, Acharya, Milin, Stromberg, Katherine, Li, Xiang, Beeharry, Neil, Maffeo, John, Jacob, Joseph M
Published in Journal of clinical oncology (20.02.2022)
Published in Journal of clinical oncology (20.02.2022)
Get full text
Journal Article
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
Kikuchi, Eiji, Gupta, Shilpa, Loriot, Yohann, Van Der Heijden, Michiel Simon, Bedke, Jens, Valderrama, Begoña Pérez, Flechon, Aude, Petrylak, Daniel P., De Santis, Maria, Galsky, Matt D., Lee, Jae Lyun, Swami, Umang, Sridhar, Srikala S., De Giorgi, Ugo, Wright, Phoebe, Lu, Yi-Tsung, Guan, Xuesong, Dillon, Ryan, Homet Moreno, Blanca, Powles, Thomas
Published in Journal of clinical oncology (10.08.2024)
Published in Journal of clinical oncology (10.08.2024)
Get full text
Journal Article
A Prospective Study of Chemoradiotherapy as Primary Treatment in Patients With Locoregionally Advanced Penile Carcinoma
Ottenhof, Sarah Rosanne, de Vries, Hielke Martijn, Doodeman, Barry, Vrijenhoek, Gerbert Lambertus, van der Noort, Vincent, Donswijk, Maarten Lucas, de Feijter, Jeantine Martina, Schaake, Eva Eline, Horenblas, Simon, Brouwer, Oscar Roberto, van der Heijden, Michiel Simon, Pos, Floris Jop
Published in International journal of radiation oncology, biology, physics (01.09.2023)
Published in International journal of radiation oncology, biology, physics (01.09.2023)
Get full text
Journal Article
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39
Van Der Heijden, Michiel Simon, Gupta, Shilpa, Bedke, Jens, Valderrama, Begoña Pérez, Kikuchi, Eiji, Iyer, Gopa, Loriot, Yohann, Dawson, Nancy Ann, Hoffman-Censits, Jean H., Mar, Nataliya, Sridhar, Srikala S., Maroto-Rey, Pablo, Shin, Sang Joon, Yu, Evan Y., Duran, Ignacio, Birrenkott, Matthew, Yu, Xuesong, Shetty, Aditya, Bavle, Abhishek Amar, Powles, Thomas
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Clinical efficacy and biomarker analysis of pre-operative ipilimumab plus nivolumab in stage III urothelial cancer: The NABUCCO trial update
Stockem, Chantal, Gil Jimenez, Alberto, van Dorp, Jeroen, Van Dijk, Nick, van Montfoort, Maurits L, Alkemade, Maartje, Seignette, Iris M., Broeks, Annegien, Hooijberg, Erik, Brugman, Wim, Mertens, Laura, van Rhijn, Bas W.G., De Feijter, Jeantine M, van der Heijden, Toine, Mehra, Niven, Meijer, Richard P., Suelmann, Britt, Vis, Daniel J, Wessels, Lodewyk F.A., Van Der Heijden, Michiel Simon
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39
Bedke, Jens, Van Der Heijden, Michiel Simon, Powles, Thomas, Valderrama, Begoña Pérez, Kikuchi, Eiji, Iyer, Gopa, Vulsteke, Christof, Swami, Umang, Castellano, Daniel, Sarwar, Naveed, Drakaki, Alexandra, Hoffman-Censits, Jean H., Arafat, Waddah, Andabekov, Timur, Li, Jian-Ri, Lu, Yi-Tsung, Yu, Xuesong, Shetty, Aditya, Homet Moreno, Blanca, Gupta, Shilpa
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer
Grivas, Petros, Morales-Barrera, Rafael, Sridhar, Srikala S., Loriot, Yohann, Van Der Heijden, Michiel Simon, Galsky, Matt D., Baxter, Dawn, Khaled, Ahmed Hussein, Hug, Bruce A.
Published in Journal of clinical oncology (20.02.2021)
Published in Journal of clinical oncology (20.02.2021)
Get full text
Journal Article
Somatostatin receptor 1 ( SSTR1 ) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC)
Zhu, Xiaolin, Vis, Daniel J, Sjöström, Martin, Shrestha, Raunak, Kneppers, Jeroen, Severson, Tessa, Zhu, Yanyun, Li, Haolong, Farsh, Tatyanah, Zhang, Meng, Lundberg, Arian, Moreno Rodriguez, Thaidy, Foye, Adam, Bergman, Andre M., Zwart, Wilbert, Quigley, David Alan, Aggarwal, Rahul Raj, Small, Eric J., Van Der Heijden, Michiel Simon, Feng, Felix Y
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study
Van Der Heijden, Michiel Simon, Powles, Thomas, Gupta, Shilpa, Bedke, Jens, Kikuchi, Eiji, De Wit, Ronald, Galsky, Matt D., Duran, Ignacio, Necchi, Andrea, Retz, Margitta, Yu, Evan Y., Hoffman-Censits, Jean H., Iyer, Gopa, Park, Se Hoon, Su, Wen-Pin, Parmar, Hema, Guan, Xuesong, Gorla, Seema Rao, Homet Moreno, Blanca, Valderrama, Begoña Pérez
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study
Jacob, Joseph M, Guerrero-Ramos, Félix, Xylinas, Evanguelos, Simone, Giuseppe, Lotan, Yair, Pieczonka, Christopher Michael, Arentsen, Harm, Necchi, Andrea, Kulkarni, Girish S., Patel, Manish, Cahn, David J, Nam, Jong Kil, Boegemann, Martin, Hampras, Shalaka, Stromberg, Katherine, Martin, Jason L., Shulka, Abhijit, Sweiti, Hussein, Van Der Heijden, Michiel Simon
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
Clinical results of PERICLES: A phase II trial investigating atezolizumab +/- radiotherapy for advanced squamous cell carcinoma of the penis
de Vries, Hielke Martijn, De Feijter, Jeantine, Bekers, Elise, Lopez-Yurda, Marta, Pos, Floris J., Horenblas, Simon, Jordanova, Ekatarina S., Brouwer, Oscar R., Schaake, Eva E., Van Der Heijden, Michiel Simon
Published in Journal of clinical oncology (20.02.2022)
Published in Journal of clinical oncology (20.02.2022)
Get full text
Journal Article
Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study
Weickhardt, Andrew James, Van Der Heijden, Michiel Simon, Balar, Arjun Vasant, Shariat, Shahrokh F., Shore, Neal D., Fang, Xiao, Godwin, James Luke, Kapadia, Ekta, Michalski, Jeff M., James, Nicholas D.
Published in Journal of clinical oncology (20.02.2021)
Published in Journal of clinical oncology (20.02.2021)
Get full text
Journal Article
A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA)
Powles, Thomas, Meeks, Joshua J, Galsky, Matt D., Van Der Heijden, Michiel Simon, Nishiyama, Hiroyuki, Al-Ahmadie, Hikmat A, Goluboff, Erik T., Hois, Stephan, Donegan, Sarah E., Williams, Vanessa, Xiao, Feng, Catto, James WF
Published in Journal of clinical oncology (20.02.2021)
Published in Journal of clinical oncology (20.02.2021)
Get full text
Journal Article
A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC)
Sonpavde, Guru, Necchi, Andrea, Gupta, Shilpa, Steinberg, Gary D., Gschwend, Juergen, Van Der Heijden, Michiel Simon, Richiero, Audrey, Lambert, Alexandre, Raybold, Bradley, Gajavelli, Srikanth, Zardavas, Dimitrios, Galsky, Matt D.
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992
Balar, Arjun Vasant, James, Nicholas D., Shariat, Shahrokh F., Shore, Neal D., Van Der Heijden, Michiel Simon, Weickhardt, Andrew James, Fang, Xiao, Godwin, James Luke, Kapadia, Ekta, Michalski, Jeff M.
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2
McGregor, Bradley Alexander, Balar, Arjun Vasant, Rosenberg, Jonathan E., Van Der Heijden, Michiel Simon, Park, Se Hoon, Lee, Jae-Lyun, Kojima, Takahiro, Harrison, Michael Roger, Heath, Elisabeth I., Stein, Mark N., Loriot, Yohann, Necchi, Andrea, Steinberg, Joyce Leta, Liang, Shang-Ying, Trowbridge, Janet, Petrylak, Daniel P., Yu, Evan Y.
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article